anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Reproductive Toxicology

Anastrozole has been found to cross the placenta following oral administration of 0.1 mg/kg in rats and rabbits (about 1 and 1.9 times the recommended human dose, respectively, on a mg/m2 basis). Studies in both rats and rabbits at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively (about 1 and 1/3, respectively, the recommended human dose on a mg/m2 basis), administered during the period of organogenesis showed that anastrozole increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses); effects were dose related in rats. Placental weights were significantly increased in rats at doses of 0.1 mg/kg/day or more.

Evidence of fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), was observed in rats administered doses of 1 mg/kg/day (which produced plasma anastrozole Cssmax and AUC0-24 hr that were 19 times and 9 times higher than the respective values found in postmenopausal volunteers at the recommended dose). There was no evidence of teratogenicity in rats administered doses up to 1.0 mg/kg/day. In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1.0 mg/kg/day (about 16 times the recommended human dose on a mg/m2 basis); there was no evidence of teratogenicity in rabbits administered 0.2 mg/kg/day (about 3 times the recommended human dose on a mg/m2 basis).
A new method of designing and generating compounds having an increased probability of being drugs, drug candidates, or biologically active compounds, in particular having a therapeutic utility, is disclosed. The method consists of identifying a group of bioactive compounds, preferably of diverse therapeutic uses or biological activities and built on a common building block. In this group of compounds, side chains modifying the building block are identified and used to generate a second set of compounds according to the proposed methods of "hybridization", "single substitution" or "incorporation of frequently used side chains". If the compounds in the second set built on the same building block contain an unusually large number of drugs, preferably with diverse therapeutic uses or biological activities, they constitute a "hot spot". A focused combinatorial library of the "hot spot" is then generated, preferably by methods of combinatorial chemistry, and compounds of this library are screened for a variety of therapeutic uses or biological activities. The method generates drugs, drug candidates, or biologically active compounds with a high probability, without requiring any prior knowledge of biological targets.
During the last decade, novel approaches for cancer treatment have been developed. Antitumor vaccines are one of the most promising approaches in tumor immunotherapy. Tumor cells possess low immunogenicity properties due to a number of the not completely understood mechanisms of resistance. One of the ways to overcome it is immune genes transfection. Genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and IL-12 have been used most commonly, both in preclinical studies and clinical trials. These cytokines are well known to participate in the systemic immune response. Several studies have shown that the professional antigen-presenting cells (APCs) of the host, rather than the vaccinating tumor cells themselves, are responsible for priming CD4+ and CD8+ T cells, both of which are required to generate systemic antitumor immunity. Recent findings indicate that the adaptive arm of immunity is governed by the innate immune mechanisms that control the co-stimulatory signaling of APCs. Recently, investigators identified a novel gene, tag7, also know as PGRP-S. The insect ortholog of the tag7/PGRP-S was shown to be involved in the innate immune response in Drosophila. In preclinical studies, tag7-modified mouse tumor cells induced a long-lasting T-cell dependent immune response in mice. The effectiveness of antitumor vaccination was demonstrated on different models of mouse tumors, particularly for melanoma cells (M3, B16, F10). Clinically important results of vaccine therapy were achieved in patients with melanoma and renal carcinoma in a number of studies. The results with this treatment are comparable to chemotherapy and immunotherapy. Investigators assume that one has to activate the innate component of immunity first, followed by the activation of the adaptive one, to make anticancer vaccines more effective. Thus, a phase I/II clinical trial has been performed to evaluate the feasibility and toxicity of treatment with autologous tumor cells modified with the tag7 gene, which has been shown to be involved in innate immunity mechanisms,
PURPOSE:To lessen the change in photographic performance at the time of preservation by preserving the photosensitive material contg. an emulsion sensitized by a gold compd. and a chalcogenide compd. and a dye which does not generate HCN in a hermetic container. CONSTITUTION:The emulsion chemically sensitized by the gold compd. and the chalcogenide compd. and the prescribed dye (A) are incorporated into this photosensitive material. The photosensitive material is preserved in the hermetic container which can maintain the specified relative humidity. Such a dye (e.g.: the compd. of formula) which does not generate the HCN and does not substan tially deteriorate the photographic characteristics of the photosensitive material by this HCN is used for this dye A. The above-mentioned relative humidity is preferably specified to 50 to 70% at 20 deg.C.
In Group I; The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
The present disclosure relates to a method, a device and a medium for performing vessel segmentation in a medical image. The method may comprise acquiring a medical image for vessel segmentation containing multiple parts, each of which contains vessels with different structural attributes. The method may comprise dividing the medical image into sub-medical images according to the parts by using a processor. The method may comprise determining individual vessel segmentation result for each part by means of using the vessel segmentation model corresponding to the part based on the sub-medical image of the part by using the processor. The method may comprise obtaining a vessel segmentation result of the medical image by means of fusing the individual vessel segmentation results of the sub-medical images of the parts by the processor. By applying the method and the device, vessel segmentation models are adapted differentially for the individual parts so as to segment the vessels of the individual parts respectively, so that the entire vessel segmentation process is fast, effective, and accurate.
The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
Disclosed is a skin antiseptic agent which hardly causes a skin disorder such as rough skin and has a prolonged antiseptic effect. Also disclosed is a skin disinfection method which hardly causes a skin disorder such as rough skin and enables a prolonged antiseptic effect. The skin antiseptic agent comprises an N-acylated form of hydroxyproline or a salt thereof. A preferred example of the N-acylated form of hydroxyproline or the salt thereof is N-acetylhydroxyproline. Preferred examples of the antiseptic component include alcohols such as ethanol and isopropyl alcohol. The skin disinfection method may comprise applying or spraying a composition comprising an N-acylated form of hydroxyproline or a salt thereof onto the skin. The composition is preferably the skin antiseptic agent.
PURPOSE: A pharmaceutical composition or a feed composition containing Angelica gigas Nakai as an active ingredient for preventing or treating coccidiosis is provided to remarkably reduce mortality rate of chickens caused by Eimeria maxima, and to be used as a drug or a feed additive for preventing or treating coccidiosis in livestock, especially in poultry. CONSTITUTION: A pharmaceutical composition for preventing or treating coccidiosis contains Angelica gigas Nakai as an active ingredient. Coccidiosis is caused from poultry. The aerial part of Angelica gigas Nakai is extracted using water, C1-C6 alcohol, or a mixture thereof. A feed contains 0.1-0.5 wt% of Angelica gigas Nakai extract. The root part of Angelica gigas Nakai is powder type. The feed contains 1.0-2.0 wt% of power of the root part. A feed composition for preventing or treating coccidiosis contains the feed composition as an active ingredient. [Reference numerals] (AA) Effect of Angelica gigas Nakai aerial part ethanol extract to the reduction of death rate; (BB) Group; (CC) Survival rate; (DD,HH) Angelica gigas Nakai 0.1%; (EE,II) Angelica gigas Nakai 0.3%; (FF,JJ) Angelica gigas Nakai 0.5%; (GG,KK) Control group; (LL) Eimeria maxima infection; (MM) No infection; (NN) Dead number/Total number(Survival rate)
Participants will receive roxadustat capsules at 50 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
Randomized controlled trial (Study 1) will feature post-bariatric patients in outpatient care at the public health unit. The post-bariatric patients will be randomized through a random code generator software (www.randomization.com) at a ratio of 1:1, into two groups: a) Intervention group - that will perform a supervised RT program for 6-months or b) Non-exercised control group - that will receive the standard clinical follow-up and shall not change their physical activity behavior. The exercise sessions will include: a) 10-min specific warm-up, consisting of one set of 20 repetitions with loads corresponding to 50% of the resistance used in the first exercise of the training session; b) 45-min of resistance exercises for the upper and lower body (8 single and multi-joint exercises with free weights and machines, including seated rowing, leg press, bench press, leg flexion, pull down, leg extension, shoulder press, and abdominal exercises), performed with 2-3 sets of 8 to 12 repetitions with loads ≥ 70% of one-repetition maximum (1RM) interspersed with 2 min intervals between sets; c) 5-min recovery with stretch and cool-down exercises. During six months, all training sessions will occur three times a week on nonconsecutive days. The outcomes will be assessed by dual energy X-ray emission densitometry (DXA); high resolution peripheral quantitative computed tomography (HR-pQCT), repetition maximum, handgrip strength; biochemical analysis (blood lipid profile, blood glucose and biomarkers of bone formation and absorption and calcium metabolism); venous occlusion plethysmography and nailfold videocapillaroscopy; blood pressure measurement and 36-Item Short-form Health Survey. The cross-sectional study (Study 2) will have 2 groups: post-bariatric patients group (BG) and control group (CG) - non-bariatric controls. Outcomes will be assessed by DXA; HR-pQCT; handgrip strength and biochemical analysis (blood lipid profile, blood glucose and biomarkers of bone formation and absorption and calcium metabolism).
PURPOSE:To provide the subject new recombinant cell capable of highly manifesting the objective polypeptide. CONSTITUTION:A vector having a nucleotide sequence coding a polypeptide, another nucleotide sequence amplifying it and imparting resistance properties against a selected chemical to a mammal cell and one more nucleotide sequence controlling manifestation of both the nucleotide sequences is introduced into a mammal cell. From the resultant recombinant cells, recombinant cells exhibiting resistance against the selected chemical are separated each in the form of a unicell-derived recombinant cell. Candidate recombinant cells capable of highly manifesting a polypeptide are selected by quantitative analysis of the polypeptide-manifestation properties. The selected candidate cells are then cultured several times each in a culture medium containing a gradually increased concentration of the selected chemical, thus selecting the objective recombinant cell capable of highly manifesting a polypeptide. For example, hTGF-beta1- producing cell strain 29E6-2 (FERM BP-3218) highly manifesting hTGF-beta1 is selected out.
<P>PROBLEM TO BE SOLVED: To provide a means which contains a sphingoglycolipid and/or a phytosterolglycoside, strengthens the interfaces of microemulsion particles, and prevents the uniting of the microemulsion under high temperature storage conditions.  <P>SOLUTION: This external preparation for the skins is characterized by comprising (1) a sphingoglycolipid and/or a phytosterolglycoside, and (2) L-carnitine and/or its salt. The dosage form of the external preparation for the skins is preferably a water-in-oil type emulsion form. It is preferable to contain the sphingoglycolipid and/or the phytosterolglycoside in the form of the microemulsion. The microemulsion is preferable to be a microemulsion formed from a phospholipid.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The association between Attention Deficit Hyperactivity Disorder (ADHD) and low-grade inflammation has been explored in children but rarely in adults. Inflammation is characteristic of some, but not all, patients with ADHD and might be influenced by ADHD medication but also lifestyle factors including nutrition, smoking, and stress. It is also still unclear if any specific symptoms are related to inflammation. Therefore, we assessed 96 inflammatory proteins in a deeply phenotyped cohort of 126 adult ADHD participants with a stable medication status using OLINK technology. A data-based, unsupervised hierarchical clustering method could identify two distinct biotypes within the 126 ADHD participants based on their inflammatory profile: a higher inflammatory potential (HIP) and a lower inflammatory protein potential (LIP) group. Biological processes that differed strongest between groups were related to the NF-κB pathway, chemokine signaling, IL-17 signaling, metabolic alterations, and chemokine attraction. A comparison of sample characteristics revealed that the HIP group was more likely to have higher levels of chronic stress (p < 0.001), a higher clinical global impression scale score (p = 0.030), and a higher risk for suicide (p = 0.032). Medication status did not influence protein levels significantly (p ≥ 0.074), but psychotropic co-medication (p ≤ 0.009) did. In conclusion, our data suggest the presence of two distinct biotypes in adults with ADHD. Higher levels of inflammatory proteins in ADHD are linked to higher levels of chronic perceived stress in a linear fashion. Further research on inflammation in adults with ADHD should take stress levels into account.
PURPOSE: Adolescent and young adult patients occupy a clinically transitional space between pediatric and adult care. Youth with chronic conditions and special healthcare needs may have trouble accessing and receiving appropriate care in this transition, which may lead to patient safety issues and medicolegal risks for physicians. The objectives of this article were to explore patient safety issues and identify medicolegal risks for physicians.
METHODS: A national repository was retrospectively searched for medicolegal cases (MLCs) involving complaints from youth. The study included MLCs closed at the Canadian Medical Protective Association between 2013 and 2022 involving youth. The study participants were adolescents and young adults aged ≥ 15 and ≤ 21 years with medical complexity. The frequencies and proportions of patient safety events and medicolegal risks for physicians were calculated by exploring factors that contributed to each incident using established frameworks.
RESULTS: A total of 182 eligible MLCs were identified. Of 206 involved physicians, 55 were psychiatrists. The most common reasons for patient complaints were deficient assessment, diagnostic error, and communication breakdown with the patient and/or family. More than half of the cases were related to a harmful incident. Peer experts reviewed the cases and identified factors such as a deficient assessment, a failure to perform a test or intervention, failure to refer the patient, and insufficient provider knowledge/skill as contributing to the patient safety event.
DISCUSSION: The impact of our findings is to identify gaps in care delivery to youth that can inform practitioners of ways to mitigate the gaps and improve patient care and health outcomes.
<P>PROBLEM TO BE SOLVED: To prepare an oil solution for cosmetics excellent in a gloss-imparting property and a water-holding property which are characteristic properties of lanolin and further excellent in compatibility with other oil solutions, and a cosmetic excellent in gloss, moisture retention and feelings upon use.  <P>SOLUTION: The oil solution for cosmetics comprises an alkenylsuccinic acid, a sterol and an alkenylsuccinate obtained by esterifying a monohydric alcohol and/or a dihydric alcohol. The cosmetic comprises the oil solution for cosmetics. The present invention provides the oil solution for the cosmetics excellent in the gloss-imparting property and the water-holding property which are characteristic properties of lanolin, and further, excellent in feelings upon use and compatibility with other oil solutions. The present invention further provides the cosmetic excellent in feelings upon use, e.g. gloss, moisture retention, slip and softness by formulating the oil solution for cosmetics.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
Participants were randomly assigned to one of two conditions: intervention or control. Intervention participants engaged in a 4 session program named the EMERGE program focused on identity development (emerging adults) or support for emerging adults (parents). Control participants received referrals to community agencies for behavioral and mental health support as needed.
Subjects in the TQLB group will receive the TQLB containing 30mL of 0.5% Bupivacaine Hydrochloride (HCL) plus PCI containing 20 mL of 0.25% of Bupivacaine Hydrochloride (HCL). For PCI, subjects will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
To explore the 2 year PFS of patients with stage III nasopharyngeal carcinoma of pretreatment EBV DNA\<4000 copy/ml treated with induction chemotherapy followed by reduced-dose radiation and cisplatin. The enrolled patients will receive 2 cycles of TPF regimen induction chemotherapy, if radiographic CR/PR and EBV DNA=0 after induction chemotherapy, the patients will be delivered by 60 Gy IMRT combined with 3 cycles of cisplatin concurrent chemotherapy. If radiographic SD/PD or EBV DNA\>0 after induction chemotherapy, the patients will receive a total of 70 Gy IMRT combined with 3 cycles of cisplatin concurrent chemotherapy.

The included patients will be treated with 2 cycles of TPF regimen induction chemotherapy and 60Gy IMRT combined with cisplatin concurrent chemotherapy. The TPF regimen is consist of paclitaxel liposome 135mg/m2 d1, cisplatin 25mg/m2d1-d3 and 5-Fu 3750mg/m2 civ120h, with a total of two cycles. Concurrent cisplatin chemotherapy is delivered with dose of 100mg/m2, a total of three cycles. The third cycle of cisplatin concurrent chemotherapy is allowed to be delivered within one week after IMRT finished.
Post Traumatic Knee Osteoarthritis (PTOA) is a degenerative joint disease resulting in the loss of cartilage due to wear and tear or by an uncharacteristic force applied to the knee. This disease appears frequently in Active-Duty Service Members and is rising in prominence where over 20,000 Knee Osteoarthritis (KOA) cases were detected over a 10-year period. Current treatments such as physical therapy (PT), braces, oral pain relievers, corticosteroid, and hyaluronic acid injections for KOA only address the quality of life and the symptoms but have not demonstrated a reverse in disease progression. Studies have found that Platelet-Rich Plasma (PRP) has shown to be a promising treatment 6-12 months post procedure and may slow KOA progression.

Photobiomodulation therapy (PBMT) is a non-invasive treatment option shown to reduce pain, increase function, and decrease stiffness with or without therapeutic exercises in KOA patients. In combination, PRP and PBMT may increase the recovery benefits while and potentially reduce KOA progression while seeking therapy. The exact dosage for the optimization of treatment with both PRP and PBMT still needs to be analyzed and understood. Therefore, this study will investigate four treatment arms utilizing PT, PT plus PRP, PT plus PBMT, and PT plus PRP plus PBMT. This discover based and randomized control trial will investigate the effect of PBMT and intra-articular administered PRP treatment on clinical outcomes (e.g., pain scores) and biomolecular signatures (DNA, RNA, or protein levels) in the blood or synovial spaces.The participants' intersectionality between pain, functionality, and precision medicine markers will be analyzed across treatment groups. Follow-up data in the form of questionnaires and activity logs will be collected to monitor study progression.